Research progress on the improvement of myocardial fibrosis by traditional Chinese medicine through regulation of NLRP3 inflammasome
- VernacularTitle:中药调控NLRP3炎症小体改善心肌纤维化的研究进展
- Author:
Rui ZHANG
1
;
Jingshun YAN
1
;
Fuyun JIA
1
;
Kexin JIA
1
;
Chenyang LIU
1
;
Yan LIU
2
;
Ye LI
2
;
Qiang XU
2
Author Information
1. Graduate School，Tianjin University of Traditional Chinese Medicine，Tianjin 301617，China
2. Dept. of Cardiology，the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine，Tianjin 300150，China
- Publication Type:Journal Article
- Keywords:
active component of TCM;
TCM formula;
myocardial fibrosis;
NLRP3 inflammasome;
mechanism of action
- From:
China Pharmacy
2025;36(8):1008-1012
- CountryChina
- Language:Chinese
-
Abstract:
Myocardial fibrosis （MF）， characterized by decreased cardiac function and myocardial compliance， is a pathological process and a progression factor in various cardiovascular diseases. The nucleotide-binding domain leucine-rich repeat and pyrin domain-containing receptor 3 （NLRP3） inflammasome is closely related to the development of MF. Recent studies have shown that traditional Chinese medicine （TCM） can regulate the NLRP3 inflammasome to alleviate MF. Based on this， this article systematically summarizes the research progress on the mechanisms by which TCM regulates the NLRP3 inflammasome to improve MF. It is found that active ingredients of TCM， such as alkaloids （lycorine，vincristine，bufalin）， saponins （astragaloside Ⅳ， diosgenin，ginsenoside Rg3）， terpenoids （celastrol，oridonin）， and phenols （polydatin，curcumin，phloridzin） as well as TCM formulas （Zhachong shisanwei pills，Zhilong huoxue tongyu capsules， Luqi formula） can inhibit the activation of the NLRP3 inflammasome， thereby suppressing the release of inflammatory factors such as interleukin-1β and IL-18， reducing inflammatory damage to myocardial tissue， alleviating excessive deposition of the extracellular matrix， and thus exerting the effect of improving MF.
